Abstract：
BACKGROUND: Bisphosphonates (BPs) are widely used in clinical practice to prevent and treat bone metabolism-related diseases. Medication-related osteonecrosis of the jaw (MRONJ) is one of the major sequelae of BPs use. Early prediction and intervention of MRONJ are of great significance.
METHODS: Ninety-seven patients currently on treatment with BPs or with a history of BPs usage and 45 healthy volunteers undergoing dentoalveolar surgery were included in this study. Participants\' serum Semaphorin 4D (Sema4D) levels were measured and analyzed before participants underwent surgery (T0) and after a 12-month follow-up (T1). Kruskal-Wallis test and ROC analysis were used to examine the predictive effect of Sema4D on MRONJ.
RESULTS: Sema4D levels in serum of patients corresponding to confirmed MRONJ were significantly lower at both T0 and T1 time points compared to non-MRONJ and healthy controls. Sema4D has a statistically predictive effect on the occurrence and diagnosis of MRONJ. Serum Sema4D levels were significantly reduced in MRONJ class 3 patients. MRONJ patients who received intravenous BPs had significantly lower Sema4D levels than those who received oral BPs.
CONCLUSIONS: Serum Sema4D level has predictive value for the onset of MRONJ in BPs users within 12 weeks after dentoalveolar surgery.
METHODS: Ninety-seven patients currently on treatment with BPs or with a history of BPs usage and 45 healthy volunteers undergoing dentoalveolar surgery were included in this study. Participants\' serum Semaphorin 4D (Sema4D) levels were measured and analyzed before participants underwent surgery (T0) and after a 12-month follow-up (T1). Kruskal-Wallis test and ROC analysis were used to examine the predictive effect of Sema4D on MRONJ.
RESULTS: Sema4D levels in serum of patients corresponding to confirmed MRONJ were significantly lower at both T0 and T1 time points compared to non-MRONJ and healthy controls. Sema4D has a statistically predictive effect on the occurrence and diagnosis of MRONJ. Serum Sema4D levels were significantly reduced in MRONJ class 3 patients. MRONJ patients who received intravenous BPs had significantly lower Sema4D levels than those who received oral BPs.
CONCLUSIONS: Serum Sema4D level has predictive value for the onset of MRONJ in BPs users within 12 weeks after dentoalveolar surgery.
摘要：
背景：双膦酸盐（BP）在临床实践中被广泛用于预防和治疗骨代谢相关疾病。药物相关的颌骨坏死（MRONJ）是BP使用的主要后遗症之一。MRONJ的早期预测和干预具有重要意义。
方法：本研究纳入了97例目前正在接受BPs治疗或有BPs使用史的患者和45例接受牙槽骨手术的健康志愿者。在参与者接受手术前（T0）和12个月随访后（T1）测量和分析参与者的血清信号蛋白4D（Sema4D）水平。使用Kruskal-Wallis检验和ROC分析来检查Sema4D对MRONJ的预测效果。
结果：与非MRONJ和健康对照相比，在T0和T1时间点，对应于确认的MRONJ的患者血清中的Sema4D水平均显着降低。Sema4D对MRONJ的发生和诊断具有统计学上的猜测感化。MRONJ3类患者血清Sema4D水平显著降低。接受静脉BPs的MRONJ患者的Sema4D水平明显低于接受口服BPs的患者。
结论：牙槽骨手术后12周内，血清Sema4D水平对BPs使用者MRONJ的发作具有预测价值。
方法：本研究纳入了97例目前正在接受BPs治疗或有BPs使用史的患者和45例接受牙槽骨手术的健康志愿者。在参与者接受手术前（T0）和12个月随访后（T1）测量和分析参与者的血清信号蛋白4D（Sema4D）水平。使用Kruskal-Wallis检验和ROC分析来检查Sema4D对MRONJ的预测效果。
结果：与非MRONJ和健康对照相比，在T0和T1时间点，对应于确认的MRONJ的患者血清中的Sema4D水平均显着降低。Sema4D对MRONJ的发生和诊断具有统计学上的猜测感化。MRONJ3类患者血清Sema4D水平显著降低。接受静脉BPs的MRONJ患者的Sema4D水平明显低于接受口服BPs的患者。
结论：牙槽骨手术后12周内，血清Sema4D水平对BPs使用者MRONJ的发作具有预测价值。
